Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-FAB™
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • Preferential rights issue 2021
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • SV

  • Tumor-directed immunotherapy of cancer

Latest News

  • 22 Apr 2021 – The Nomination Committee’s proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB
  • 15 Apr 2021 – Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
  • 3 Apr 2021 – Alligator Bioscience postpones the Annual General Meeting to June 1, 2021
  • 18 Mar 2021 – Alligator Bioscience appoints Søren Bregenholt as new CEO
More news

Calendar

  • 20 Apr 2021 — 23 Apr 2021 ‐ NLSDays 2021
  • 27 Apr 2021 ‐ Interim report January-March 2021
  • 17 May 2021 ‐ Nordea Småbolagshörnan
  • 25 May 2021 ‐ ABGSC Life Science Summit
  • 26 May 2021 ‐ Life Science Investor conference, Köpenhamn
  • 4 Jun 2021 — 8 Jun 2021 ‐ 2021 ASCO Annual Meeting

INTERVIEW

Interim CEO Malin Carlsson comments the research collaboration with US MacroGenics and the latest development with mitazalimab and ATOR-1017.

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact
  • Privacy policy

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.I agreeI do not agree